OTC - ACTIVE INGREDIENT SECTION
carbamide peroxide
carbamide peroxide
polyvinyl pyrrolidone (k=90), glycerin, anhydrous ethyl alcohol, distilled water, potassium dihydrogen phosphate, sodium hydroxide, lemon oil, orange oil, xylitol, l-menthol, potassium nitrate, propolis ext
whitening of discolored vital teeth
keep out of reach of the children
apply 2 or 3 times per day for 2 weeks for a brighter, whiter smile
1) do not use on patient with sensitive to carbamide peroxide
2) do not use on patient with oral infection
3) no to be used by pregnant or lactating women or children under 18 years old
4) to be used under the supervision of a dentist
5) do not swallow this medication
for dental use only
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 5eb9f24b-9328-475e-af0a-18021935eb6a | Product name | 1 | 20180220 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 47649-9001-1 | 2024-01-30 | C162847 | 48780-1 | 1030e365-2da7-111a-e063-dadaa90a10e2 | Drug Facts |
| 47649-9001-3 | 2024-01-30 | C162847 | 48780-1 | 1030e365-2da7-111a-e063-dadaa90a10e2 | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 47649-9001-1 | Dr. Whitiss (8.3%) | 5 g in 1 PACKAGE | GEL, DENTIFRICE | 5 | 3 | |
| 47649-9001-2 | Dr. Whitiss (8.3%) | 2 g in 1 CYLINDER | GEL, DENTIFRICE | 2 | 3 | |
| 47649-9001-3 | Dr. Whitiss (8.3%) | 4 in 1 PACKAGE | GEL, DENTIFRICE | 4 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 47649-9001 | DR. WHITISS (8.3%) (CARBAMIDE PEROXIDE) GEL, DENTIFRICE [NIBEC CO., LTD] | 3 | Legacy NDC, 3 package rows | 20171128_1f4d7ad3-433c-40b3-842e-73a327214d86.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBAMIDE PEROXIDE | ACTIVE INGREDIENT | 31PZ2VAU81 | 1 | |
| HYDROGEN PEROXIDE | ACTIVE MOIETY | BBX060AN9V | 1 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| POTASSIUM NITRATE | INACTIVE INGREDIENT | RU45X2JN0Z | 1 | |
| POVIDONE K90 | INACTIVE INGREDIENT | RDH86HJV5Z | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 47649-9001 | 47649-9001-2, 47649-9001-3, 47649-9001-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POVIDONE K90 | RDH86HJV5Z | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| WATER | 059QF0KO0R | IACT |
| POTASSIUM NITRATE | RU45X2JN0Z | IACT |
| CARBAMIDE PEROXIDE | 31PZ2VAU81 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SUSPENSION / ORAL | 2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | TABLET, FILM COATED / ORAL | 128 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SOLUTION / TOPICAL | 120 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | TABLET, COATED / ORAL | 9.77 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | TABLET, EXTENDED RELEASE / ORAL | 498 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SOLUTION/ DROPS / OPHTHALMIC | 1.2 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SOLUTION / OPHTHALMIC | 0.3 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SOLUTION/ DROPS / AURICULAR (OTIC) | 2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | TABLET / ORAL | 966 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | CAPSULE / ORAL | 270 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | TABLET, DELAYED RELEASE / ORAL | 192 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SYSTEM / TOPICAL | 280 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| POVIDONE K90 | POVIDONE K90 | RDH86HJV5Z | SUSPENSION / OPHTHALMIC | 4 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5f0112bb-31bf-d5c1-e053-2a91aa0a44d5 | 1f4d7ad3-433c-40b3-842e-73a327214d86 | 2017-11-27 | Warnings | 5f0112bb-31bf-d5c1-e053-2a91aa0a44d5 1f4d7ad3-433c-40b3-842e-73a327214d86 |
Adverse event summaries are temporarily unavailable. Other product information remains available.